Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or no maintenance in patients with diffuse large B-cell lymphoma: Results from a HOVON-Nordic Lymphoma Group study Presented By Pieternella Lugtenburg at 2016 ASCO Annual Meeting

Introduction Presented By Pieternella Lugtenburg at 2016 ASCO Annual Meeting

Study design Presented By Pieternella Lugtenburg at 2016 ASCO Annual Meeting

Endpoints Presented By Pieternella Lugtenburg at 2016 ASCO Annual Meeting

5 point scale (Deauville criteria) Presented By Pieternella Lugtenburg at 2016 ASCO Annual Meeting

Inclusion and exclusion criteria Presented By Pieternella Lugtenburg at 2016 ASCO Annual Meeting

Patient baseline characteristics Presented By Pieternella Lugtenburg at 2016 ASCO Annual Meeting

Patient baseline characteristics Presented By Pieternella Lugtenburg at 2016 ASCO Annual Meeting

Patient disposition Presented By Pieternella Lugtenburg at 2016 ASCO Annual Meeting

Overview of adverse events grade Presented By Pieternella Lugtenburg at 2016 ASCO Annual Meeting

Adverse events grade patients years cycles 1- 4 Presented By Pieternella Lugtenburg at 2016 ASCO Annual Meeting

Adverse events grade patients years cycles 1- 4 Presented By Pieternella Lugtenburg at 2016 ASCO Annual Meeting

Metabolic complete remission end of induction Presented By Pieternella Lugtenburg at 2016 ASCO Annual Meeting

Progression free survival Presented By Pieternella Lugtenburg at 2016 ASCO Annual Meeting

Overall survival Presented By Pieternella Lugtenburg at 2016 ASCO Annual Meeting

Conclusions Presented By Pieternella Lugtenburg at 2016 ASCO Annual Meeting

Acknowledgements Presented By Pieternella Lugtenburg at 2016 ASCO Annual Meeting